Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization

Vaccine

Volumn 28, Issue 30, 2010, Pages 4827-4836

  Patel, Vainav ^a   Valentin, Antonio ^a   Kulkarni, Viraj ^a   Rosati, Margherita ^a   Bergamaschi, Cristina ^a   Jalah, Rashmi ^a   Alicea, Candido ^a   Minang, Jacob T ^a   Trivett, Matthew T ^a   Ohlen, Claes ^a   Zhao, Jun ^b   Robert Guroff, Marjorie ^b   Khan, Amir S ^c   Draghia Akli, Ruxandra ^c   Felber, Barbara K ^a   Pavlakis, George N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Inovio Biomedical Corporation   (United States)

Author keywords

Adjuvant; AIDS vaccine; BAL; Cellular immune response; DNA vaccine; Humoral immune response; IFN ; IL 12; Immunology; PBMC; Rectal mucosa; Rhesus macaque; TNF

Indexed keywords

DNA VACCINE; GAG PROTEIN; GAMMA INTERFERON; GRANZYME B; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 12; NEF PROTEIN; PLASMID DNA; POL PROTEIN; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; TRANSACTIVATOR PROTEIN; VIF PROTEIN; VIRUS ANTIBODY; CYTOKINE; IMMUNOGLOBULIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOLOGICAL MONITORING; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; DNA IMMUNIZATION; DRUG EFFICACY; EFFECTOR CELL; ELECTROPORATION; HUMORAL IMMUNITY; LUNG LAVAGE; MACACA; MEMORY T LYMPHOCYTE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; ADOPTIVE IMMUNOTHERAPY; ANIMAL; ANTIBODY SPECIFICITY; BLOOD; DRUG DELIVERY SYSTEM; FLOW CYTOMETRY; GENE VECTOR; GENETICS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; PROCEDURES; RHESUS MONKEY; T LYMPHOCYTE; VACCINATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; DRUG DELIVERY SYSTEMS; ELECTROPORATION; FLOW CYTOMETRY; GENE PRODUCTS, GAG; GENETIC VECTORS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, INTRAMUSCULAR; MACACA MULATTA; SAIDS VACCINES; T-LYMPHOCYTES; VACCINATION; VACCINES, DNA;

EID: 77954218164     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.04.064     Document Type: Article

References (79)

1. Haynes B.F., Shattock R.J. Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol 2008, 122(July (1)):3-9. quiz 10-1.
2. Paiardini M., Frank I., Pandrea I., Apetrei C., Silvestri G. Mucosal immune dysfunction in AIDS pathogenesis. AIDS Rev 2008, 10(January-March (1)):36-46.
3. Belyakov I.M., Berzofsky J.A. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity 2004, 20(March (3)):247-253.
4. Kutzler M.A., Weiner D.B. DNA vaccines: ready for prime time?. Nat Rev Genet 2008, 9(October (10)):776-788.
5. Yuki Y., Nochi T., Kiyono H. Progress towards an AIDS mucosal vaccine: an overview. Tuberculosis (Edinb) 2007, 87(August (Suppl. 1)):S35-S44.
6. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6(February (2)):148-158.
7. Hinkula J. Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity. Expert Rev Vaccines 2007, 6(April (2)):203-212.
8. Zhou Q., Hidajat R., Peng B., Venzon D., Aldrich M.K., Richardson E., et al. Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251). Vaccine 2007, 25(November 19 (47)):8021-8035.
9. Mercier G.T., Nehete P.N., Passeri M.F., Nehete B.N., Weaver E.A., Templeton N.S., et al. Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine 2007, 25(December 17 (52)):8687-8701.
10. + T cell responses in the gut. Vaccine 2007, 25(March 8 (12)):2187-2193.
11. + T cell functionality and mucosal homing. Virology 2007, 367(October 10 (1)):156-167.
12. Jiang S., Rasmussen R.A., Nolan K.M., Frankel F.R., Lieberman J., McClure H.M., et al. Live attenuated Listeria monocytogenes expressing HIV Gag: immunogenicity in rhesus monkeys. Vaccine 2007, 25(October 16 (42)):7470-7479.
13. Stevceva L., Alvarez X., Lackner A.A., Tryniszewska E., Kelsall B., Nacsa J., et al. Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques. J Virol 2002, 76(November (22)):11659-11676.
14. Bagarazzi M.L., Boyer J.D., Javadian M.A., Chattergoon M.A., Shah A.R., Cohen A.D., et al. Systemic and mucosal immunity is elicited after both intramuscular and intravaginal delivery of human immunodeficiency virus type 1 DNA plasmid vaccines to pregnant chimpanzees. J Infect Dis 1999, 180(October (4)):1351-1355.
15. Leung N.J., Aldovini A., Young R., Jarvis M.A., Smith J.M., Meyer D., et al. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins. Virology 2000, 268(March 1 (1)):94-103.
16. Fuller D.H., Rajakumar P.A., Wilson L.A., Trichel A.M., Fuller J.T., Shipley T., et al. Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. J Virol 2002, 76(April (7)):3309-3317.
17. Evans D.T., Chen L.M., Gillis J., Lin K.C., Harty B., Mazzara G.P., et al. Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system. J Virol 2003, 77(February (4)):2400-2409.
18. Mederle I., Le Grand R., Vaslin B., Badell E., Vingert B., Dormont D., et al. Mucosal administration of three recombinant Mycobacterium bovis BCG-SIVmac251 strains to cynomolgus macaques induces rectal IgAs and boosts systemic cellular immune responses that are primed by intradermal vaccination. Vaccine 2003, 21(October 1 (27-30)):4153-4166.
19. Pinczewski J., Zhao J., Malkevitch N., Patterson L.J., Aldrich K., Alvord W.G., et al. Enhanced immunity and protective efficacy against SIVmac251 intrarectal challenge following ad-SIV priming by multiple mucosal routes and gp120 boosting in MPL-SE. Viral Immunol 2005, 18(1):236-243.
20. Wang S.W., Kozlowski P.A., Schmelz G., Manson K., Wyand M.S., Glickman R., et al. Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions. J Virol 2000, 74(November (22)):10514-10522.
21. Neeson P., Boyer J., Kumar S., Lewis M.G., Mattias L., Veazey R., et al. A DNA prime-oral Listeria boost vaccine in rhesus macaques induces a SIV-specific CD8 T cell mucosal response characterized by high levels of alpha4beta7 integrin and an effector memory phenotype. Virology 2006, 354(October 25 (2)):299-315.
22. Wang S.W., Bertley F.M., Kozlowski P.A., Herrmann L., Manson K., Mazzara G., et al. An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS. AIDS Res Hum Retroviruses 2004, 20(August (8)):846-859.
23. + T lymphocytes to mucosal surfaces following intramuscular vaccination. J Immunol 2008, 181(September 15 (6)):4188-4198.
24. Belyakov I.M., Hel Z., Kelsall B., Kuznetsov V.A., Ahlers J.D., Nacsa J., et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med 2001, 7(December (12)):1320-1326.
25. + CTLs in delay of AIDS viral dissemination from mucosa. Blood 2006, 107(April 15 (8)):3258-3264.
26. + T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. J Virol 2006, 80(April (8)):3732-3742.
27. Bertley F.M., Kozlowski P.A., Wang S.W., Chappelle J., Patel J., Sonuyi O., et al. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J Immunol 2004, 172(March 15 (6)):3745-3757.
28. Baig J., Levy D.B., McKay P.F., Schmitz J.E., Santra S., Subbramanian R.A., et al. Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination. J Virol 2002, 76(November (22)):11484-11490.
29. Biragyn A., Belyakov I.M., Chow Y.H., Dimitrov D.S., Berzofsky J.A., Kwak L.W. DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood 2002, 100(August 15 (4)):1153-1159.
30. + CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization. Virology 2008, 381(November 10 (1)):106-115.
31. Eo S.K., Gierynska M., Kamar A.A., Rouse B.T. Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules. J Immunol 2001, 166(May 1 (9)):5473-5479.
32. Yang K., Whalen B.J., Tirabassi R.S., Selin L.K., Levchenko T.S., Torchilin V.P., et al. A DNA vaccine prime followed by a liposome-encapsulated protein boost confers enhanced mucosal immune responses and protection. J Immunol 2008, 180(May 1 (9)):6159-6167.
33. Jeyanathan M., Mu J., Kugathasan K., Zhang X., Damjanovic D., Small C., et al. Airway delivery of soluble mycobacterial antigens restores protective mucosal immunity by single intramuscular plasmid DNA tuberculosis vaccination: role of proinflammatory signals in the lung. J Immunol 2008, 181(October 15 (8)):5618-5626.
34. Tavel J.A., Martin J.E., Kelly G.G., Enama M.E., Shen J.M., Gomez P.L., et al. Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects. J Acquir Immune Defic Syndr 2007, 44(April 15 (5)):601-605.
35. Graham B.S., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006, 194(December 15 (12)):1650-1660.
36. Mwau M., Cebere I., Sutton J., Chikoti P., Winstone N., Wee E.G., et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 2004, 85(April (Pt 4)):911-919.
37. Bansal A., Jackson B., West K., Wang S., Lu S., Kennedy J.S., et al. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration. J Virol 2008, 82(July (13)):6458-6469.
38. Jaoko W., Nakwagala F.N., Anzala O., Manyonyi G.O., Birungi J., Nanvubya A., et al. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 2008, 26(May 23 (22)):2788-2795.
39. Wilson C.C., Newman M.J., Livingston B.D., MaWhinney S., Forster J.E., Scott J., et al. Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy. Clin Vaccine Immunol 2008, 15(June (6)):986-994.
40. Rosati M., von Gegerfelt A., Roth P., Alicea C., Valentin A., Robert-Guroff M., et al. DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J Virol 2005, 79(July (13)):8480-8492.
41. Wilson N.A., Reed J., Napoe G.S., Piaskowski S., Szymanski A., Furlott J., et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 2006, 80(June (12)):5875-5885.
42. Barouch D.H., Fu T.M., Montefiori D.C., Lewis M.G., Shiver J.W., Letvin N.L. Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus monkeys. Immunol Lett 2001, 79(November 1 (1-2)):57-61.
43. Egan M.A., Charini W.A., Kuroda M.J., Schmitz J.E., Racz P., Tenner-Racz K., et al. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection. J Virol 2000, 74(August (16)):7485-7495.
44. Muthumani K., Bagarazzi M., Conway D., Hwang D.S., Manson K., Ciccarelli R., et al. A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIV(mac)251 challenge in Rhesus Macaques. Vaccine 2003, 21(January 30 (7-8)):629-637.
45. Mossman S.P., Pierce C.C., Watson A.J., Robertson M.N., Montefiori D.C., Kuller L., et al. Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles. AIDS Res Hum Retroviruses 2004, 20(April (4)):425-434.
46. Koopman G., Mortier D., Hofman S., Mathy N., Koutsoukos M., Ertl P., et al. Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination. J Gen Virol 2008, 89(February (Pt 2)):540-553.
47. Aihara H., Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998, 16(September (9)):867-870.
48. Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 1999, 6(April (4)):508-514.
49. Prud'homme G.J., Glinka Y., Khan A.S., Draghia-Akli R. Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Curr Gene Ther 2006, 6(April (2)):243-273.
50. Rizzuto G., Cappelletti M., Maione D., Savino R., Lazzaro D., Costa P., et al. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci U S A 1999, 96(May 25 (11)):6417-6422.
51. Wang Z., Troilo P.J., Wang X., Griffiths T.G., Pacchione S.J., Barnum A.B., et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther 2004, 11(April (8)):711-721.
52. Widera G., Austin M., Rabussay D., Goldbeck C., Barnett S.W., Chen M., et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000, 164(9):4635-4640.
53. Otten G., Schaefer M., Doe B., Liu H., Srivastava I., zur Megede J., et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 2004, 22(June 23 (19)):2489-2493.
54. Otten G.R., Schaefer M., Doe B., Liu H., Megede J.Z., Donnelly J., et al. Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine 2006, 24(May 22 (21)):4503-4509.
55. Rosati M., Valentin A., Jalah R., Patel V., von Gegerfelt A., Bergamaschi C., et al. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 2008, 26:5223-5229.
56. Luckay A., Sidhu M.K., Kjeken R., Megati S., Chong S.Y., Roopchand V., et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 2007, 81(May (10)):5257-5269.
57. Hirao L.A., Wu L., Khan A.S., Hokey D.A., Yan J., Dai A., et al. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 2008, 26:3112-3120.
58. Rosati M., Bergamaschi C., Valentin A., Kulkarni V., Jalah R., Patel V., et al. DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proc Natl Acad Sci USA 2009, 06:15831-15836.
59. + T cell clones in rhesus macaques during acute infection. J Immunol 2009, 184(January (1)):315-326.
60. Nasioulas G., Zolotukhin A.S., Tabernero C., Solomin L., Cunningham C.P., Pavlakis G.N., et al. Elements distinct from human immunodeficiency virus type 1 splice sites are responsible for the Rev dependence of env mRNA. J Virol 1994, 68(May (5)):2986-2993.
61. Schneider R., Campbell M., Nasioulas G., Felber B.K., Pavlakis G.N. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J Virol 1997, 71(July (7)):4892-4903.
62. Schwartz S., Campbell M., Nasioulas G., Harrison J., Felber B.K., Pavlakis G.N. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J Virol 1992, 66(December (12)):7176-7182.
63. Schwartz S., Felber B.K., Pavlakis G.N. Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J Virol 1992, 66(January (1)):150-159.
64. von Gegerfelt A.S., Rosati M., Alicea C., Valentin A., Roth P., Bear J., et al. Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization. J Virol 2007, 81(February (4)):1972-1979.
65. Chikhlikar P., Barros de Arruda L., Agrawal S., Byrne B., Guggino W., August J.T., et al. Inverted terminal repeat sequences of adeno-associated virus enhance the antibody and CD8(+) responses to a HIV-1 p55Gag/LAMP DNA vaccine chimera. Virology 2004, 323(June 1 (2)):220-232.
66. Schadeck E.B., Sidhu M., Egan M.A., Chong S.Y., Piacente P., Masood A., et al. A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine 2006, 24(May 22 (21)):4677-4687.
67. Hidajat R., Xiao P., Zhou Q., Venzon D., Summers L.E., Kalyanaraman V.S., et al. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol 2009, 83(January (2)):791-801.
68. Halwani R., Boyer J.D., Yassine-Diab B., Haddad E.K., Robinson T.M., Kumar S., et al. Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA+IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques. J Immunol 2008, 180(June 15 (12)):7969-7979.
69. Boyer J.D., Robinson T.M., Kutzler M.A., Parkinson R., Calarota S.A., Sidhu M.K., et al. SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. J Med Primatol 2005, 34(October (5-6)):262-270.
70. Pitcher C.J., Hagen S.I., Walker J.M., Lum R., Mitchell B.L., Maino V.C., et al. Development and homeostasis of T cell memory in rhesus macaque. J Immunol 2002, 168(January 1 (1)):29-43.
71. Picker L.J., Reed-Inderbitzin E.F., Hagen S.I., Edgar J.B., Hansen S.G., Legasse A., et al. IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates. J Clin Invest 2006, 116(June (6)):1514-1524.
72. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., Drummond D.D., et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009, 15(February 15):293-299.
73. + T cells. Blood 2006, 107(June 15 (12)):4781-4789.
74. Wang S., Kennedy J.S., West K., Montefiori D.C., Coley S., Lawrence J., et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008, 26(February 20 (8)):1098-1110.
75. Gorse G.J., Baden L.R., Wecker M., Newman M.J., Ferrari G., Weinhold K.J., et al. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine 2008, 26(January 10 (2)):215-223.
76. Eller M.A., Eller L.A., Opollo M.S., Ouma B.J., Oballah P.O., Galley L., et al. Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans. Vaccine 2007, 25(November 7 (45)):7737-7742.
77. Catanzaro A.T., Roederer M., Koup R.A., Bailer R.T., Enama M.E., Nason M.C., et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007, 25(May 16 (20)):4085-4092.
78. Vasan S., Schlesinger S.J., Huang Y., Hurley A., Lombardo A., Chen Z., et al. Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One 2010, 5(1):e8617.
79. Lefrancois L., Puddington L. Intestinal and pulmonary mucosal T cells: local heroes fight to maintain the status quo. Annu Rev Immunol 2006, 24:681-704.